Sign in
Taking peopleNo phase

Looking for early warning signs of worsening in liver cirrhosis

Studies hospital records to find what predicts serious decline in adults with cirrhosis.

Key facts

Who runs it
Singapore General Hospital
Where
Singapore3 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Predictors of Decompensation, Acute-on-chronic Liver Failure and Mortality in Liver Cirrhosis
Status
Recruiting
People taking part
2,200 people, planned
Started
12 Aug 2022
Expected to end
12 Aug 2032
Type of study
Observational
Treatments tested
  • Observation
Record updated
27 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with liver cirrhosis (scarring of the liver). It only collects data from hospital records, with no extra visits or tests.

Age
18 years and above. Parental consent is needed if below 21 years.
Sex
All sexes can join.
Disease stage
A clinical diagnosis of liver cirrhosis.

Main reasons for not taking part

  • No clinical evidence of liver cirrhosis
  • Not willing to give informed consent

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Patients with clinical diagnosis of liver cirrhosis
  • Age 18 years and above (parental consent required if below 21 years)
  • Willing and able to provide informed consent

Who cannot take part

  • No clinical evidence of liver cirrhosis
  • Not willing to provide informed consent

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to identify factors that predict the development of decompensation, acute-on-chronic liver failure (ACLF) and death in patients with liver cirrhosis. Clinical data will be retrieved from existing hospital records. This information may help doctors to identify patients with cirrhosis who are at risk of deterioration earlier (before they develop complications) and to develop effective treatment strategies to prevent or delay these complications.

Read full original descriptionShow less

This study is designed as a prospective, non-interventional, observational study. This means that if you agree to participate in the study, you will not be required to undergo any additional hospital visits, tests, procedures or interventions other than the usual standard-of-care management that your doctor will provide. If you consent to participate in this study, you will be providing the study investigators permission to review and analyse your clinical data from the hospital clinical records. Your data will be collected throughout the course of your disease until liver transplantation or death.

The group in the trial

  • Patients with liver cirrhosis

    Treatment: Observation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Predictors of Decompensation, Acute-on-chronic Liver Failure and Mortality in Liver Cirrhosis - a Multicentre, Prospective, Observational Study From the SingHealth Chronic Liver Disease Registry (SoLiDaRity-DAM)
Plain-language title
Looking for early warning signs of worsening in liver cirrhosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
27 February 2026